BioCentury | Sep 14, 2018
Company News

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

...Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a...
...a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI...
...Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta SOLTI, Barcelona, Spain Business: Cancer Elizabeth S. Eaton Reolysin, pelareorep Oncolytics Biotech Inc. SOLTI...
BioCentury | May 10, 2018
Politics & Policy

Agency reps recommend patient-reported outcomes for regulatory decision making

In a policy review published in The Lancet Oncology , authors from international regulatory agencies recommend incorporating patient-reported outcomes (PRO) into regulatory decision making. The paper's authors include Paul Kluetz from FDA's Oncology Center of Excellence;...
BioCentury | Feb 9, 2009
Clinical News

Myocet doxorubicin: Phase I/II data

...In the open-label, Spanish Phase I/II SOLTI trial in 69 patients, Myocet plus Herceptin trastuzumab and...
BioCentury | May 20, 2002
Company News

Metabolex management update

Metabolex Inc. , Hayward Calif. Business: Metabolic Hired: Randolph Soltys as VP of preclinical development, formerly executive director of drug safety evaluation at Bristol-Myers Squibb Co. WIR Staff...
Items per page:
1 - 4 of 4
BioCentury | Sep 14, 2018
Company News

Oncolytics to conduct pilot study of oncolytic virus with SOLTI

...Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) partnered with the non-profit group SOLTI (Barcelona, Spain) to conduct a...
...a pilot study of the biotech's Reolysin pelareorep in the neoadjuvant setting for breast cancer. SOLTI...
...Biotech Inc. (TSX:ONC; NASDAQ:ONCY), Calgary, Alberta SOLTI, Barcelona, Spain Business: Cancer Elizabeth S. Eaton Reolysin, pelareorep Oncolytics Biotech Inc. SOLTI...
BioCentury | May 10, 2018
Politics & Policy

Agency reps recommend patient-reported outcomes for regulatory decision making

In a policy review published in The Lancet Oncology , authors from international regulatory agencies recommend incorporating patient-reported outcomes (PRO) into regulatory decision making. The paper's authors include Paul Kluetz from FDA's Oncology Center of Excellence;...
BioCentury | Feb 9, 2009
Clinical News

Myocet doxorubicin: Phase I/II data

...In the open-label, Spanish Phase I/II SOLTI trial in 69 patients, Myocet plus Herceptin trastuzumab and...
BioCentury | May 20, 2002
Company News

Metabolex management update

Metabolex Inc. , Hayward Calif. Business: Metabolic Hired: Randolph Soltys as VP of preclinical development, formerly executive director of drug safety evaluation at Bristol-Myers Squibb Co. WIR Staff...
Items per page:
1 - 4 of 4